Characterization of novel human leukemic cell lines selected for resistance to merbarone, a catalytic inhibitor of DNA topoisomerase II

Cancer Research

Volumn 56, Issue 11, 1996, Pages 2573-2583

  Kusumoto, Hiroki ^a,d   Rodgers, Queen E ^a   Boege, Friedrich ^c   Raimondi, Susana C ^a,b   Beck, William T ^a,b,e  

^a ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

^b UNIVERSITY OF TENNESSEE COLLEGE OF MEDICINE   (United States)

^c UNIVERSITY OF WÜRZBURG   (Germany)

^d KYUSHU UNIVERSITY   (Japan)

^e UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

7 ETHYL 10 HYDROXYCAMPTOTHECIN; ACLARUBICIN; AMSACRINE; CAMPTOTHECIN; DAUNORUBICIN; DNA TOPOISOMERASE; DNA TOPOISOMERASE (ATP HYDROLYSING); DOXORUBICIN; ETOPOSIDE; GYRASE INHIBITOR; MERBARONE; SN 22995; TENIPOSIDE; TOPOTECAN; UNCLASSIFIED DRUG;

ARTICLE; CLONOGENIC ASSAY; CONTROLLED STUDY; CROSS RESISTANCE; DNA PROTEIN COMPLEX; DRUG CYTOTOXICITY; DRUG RESISTANCE; GROWTH INHIBITION; HUMAN; HUMAN CELL; KARYOTYPE; LEUKEMIA CELL LINE; PRIORITY JOURNAL;

ANEUPLOIDY; ANTINEOPLASTIC AGENTS; CELLS, CULTURED; DNA TOPOISOMERASES, TYPE I; DNA TOPOISOMERASES, TYPE II; DNA-BINDING PROTEINS; DRUG RESISTANCE; ENZYME INHIBITORS; HUMANS; KARYOTYPING; LEUKEMIA; THIOBARBITURATES;

EID: 0030013319     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (78)

1. Liu, L. F., Liu, C., and Alberts, B. M. Type II DNA topoisomerases: enzymes that can unknot a topologically knotted DNA molecule via a reversible double-strand break. Cell, 19: 697-707, 1980
2. Yang, L., Wold, M. S., Li, J. J., Kelly, T. J., and Liu, L. F. Roles of DNA topoisomerases in simian virus 40 DNA replication in vitro. Proc. Natl. Acad. Sci. USA, 84: 950-954, 1987.
3. Brill, S. J., DiNArdo, S., Voelkel-Meiman, K., and Sternglanz, R. Need for DNA topoisomerase activity as a swivel for DNA replication for transcription of ribosomal RNA. Nature (Lond.), 326: 414-416, 1987.
4. Nelson, W. G., Liu, L. F., and Coffey, D. S. Newly replicated DNA is associated with DNA topoisomerase II in cultured rat prostatic adenocarcinoma cells. Nature (Lond.), 322: 187-189, 1986.
5. Musk, S. R., and Steel, G. G. The inhibition of cellular recovery in human tumour cells by inhibitors of topoisomerase Br. J Cancer, 62: 364-367, 1990.
6. Ross, W., Rowe, T. C., Glisson, B., Yalowich, J , and Liu, L. F. Role of topoisomerase II in mediating epipodophyllotoxin-induced DNA cleavage. Cancer Res., 44: 5857-5860, 1984.
7. Nelson, E. M., Tewey, K. M., and Liu, L. F. Mechanism of antitumor drug action: poisoning of mammalian DNA topoisomerase II on DNA by 4′-(9-acridinylamino)- methanesulfon-m-aniside. Proc Natl. Acad Sci. USA, 81: 1361-1365, 1984.
8. Tewey, K. M , Rowe, T. C., Yang, L., Halligan, B. D., and Liu, L. F. Adriamycin-induced DNA damage mediated by mammalian DNA topoisomerase II. Science (Washington DC), 226: 466-468, 1984.
9. Liu, L. F. DNA topoisomerase poisons as anti-tumor drugs. Annu. Rev. Biochem , 58: 351-375, 1989
10. Roberge, M. J , Th'ng, J., Hamaguchi, J., and Bradbury, E. M. The topoisomerase II inhibitor VM-26 induces marked changes in histone H1 kinase activity, histone H1 and H3 phosphorylation and chromosome condensation in G2 phase and mitotic BHK cells J. Cell Biol., 111: 1753-1763, 1990.
11. cdc2 tyrosine dephosphorylation, and mitotic progression in Chinese hamster ovary cells exposed to etoposide. Cancer Res., 52: 1817-1822, 1992
12. Hartwell, L. H., and Weinert, T. A. Checkpoints: controls that ensure the order of cell cycle events. Science (Washington DC), 246: 629-633, 1989.
13. Murray, A. W Creative blocks: cell-cycle checkpoints and feedback controls. Nature (Lond.), 359: 599-604, 1992.
14. Downes, C. S , Mullinger, A M., and Johnson, R. T. Inhibitors of DNA topoisomerase II prevent chromatid separation in mammalian cells but do not prevent exit from mitosis. Proc. Natl. Acad. Sci. USA, 88: 8895-8899, 1991.
15. Summer, A. T. Inhibitors of topoisomerases do not block the passage of human lymphocyte chromosomes through mitosis. J Cell Sci., 103: 105-115, 1992
16. Uemura, T., and Yanagida, M. Isolation of type I and II DNA topoisomerase mutants from fission yeast single and double mutants show different phenotypes in cell growth and chromatin organization. EMBO J., 3: 1737-1744, 1984.
17. Uemura, T , Ohkura, H , Adachi, Y., Morino, K., Shiozaki, K., and Yanagida, M. DNA iopoisomerase II is required for condensation and separation of mitotic chromosomes in S. pombe Cell, 50: 917-925, 1987.
18. Drake, F H , Hofmann, G A., Mong, S , Bartus, J. O., Hertzberg, R. P., Johnson, R. K., Mattern, M. R., and Mirabelli, C. K. In vitro and intracellular inhibition of topoisomerase II by the antitumor agent merbarone Cancer Res., 49: 2578-2583, 1989.
19. Jensen, P. B , Sørensen, B S., Demant, E. J. F., Sehested, M , Jensen, P S., Vindeløv, L., and Hansen, H H. Antagonistic effect of aclarubicin on the cytotoxicity of etoposide and 4′-(9-acridinylamino) methanesulfon-m-aniside in human small cell lung cancer cell lines and on topoisomerase II-mediated DNA cleavage. Cancer Res., 50: 3311-3316, 1990.
20. Tanabe, K., Ikegami, Y., Ishida, R., and Andoh, T. Inhibition of topoisomerase II by antitumor agents bis(2,6-dioxopiperazine) derivatives. Cancer Res , 51: 4903-4908, 1991.
21. Chen, M., and Beck, W. T Temposide-resistant CEM cells, which express mutant topoisomerase IIα, when treated with non-complex-stabilizing inhibitors of the enzyme, display no cross-resistance and reveal aberrant functions of the mutant enzyme Cancer Res., 53: 5946-5953, 1993.
22. Cooney, D. A., Covey, J. M., Kay, G. J., Dalal, M., McMahon, J. B., and Johns, D. G. Initial mechanistic studies with merbarone. Biochem. Pharmacol., 34: 3395-3398, 1985.
23. Chang, A Y., Kim, K., Glick, J , Anderson, T., Karp, D., and Johnson, D. Phase II study of taxol, merbarone, and piroxantrone in stage IV non-small-cell lung cancer: The Eastern Cooperative Oncology Group results. J. Natl Cancer Inst , 85: 388-394, 1993.
24. Jones, D. V., Jr., Ajani, J. A., Winn, R. J , Daugherty, R. N., Levin, B., and Krakoff, I H A phase II study of merbarone in patients with adenocarcinoma of the pancreas Cancer Invest., 11: 667-669, 1993.
25. Jeasen, P B , Jensen, P. S., Demant, E. J. F., Friche, E., Sørensen, B. S., Sehested, M., Wassermann, K , Vindeløv, L., Westergaard, O , and Hansen, H. H. Antagonistic effect of aclarubicin on daunorubicin-induced cytotoxicity in human small cell lung cancer cells: relationship to DNA integrity and topoisomerase II. Cancer Res., 51: 5093-5099, 1991.
26. Ishida, R., Miki, T., Narita, T., Yui, R., Sato, M , Utsumi, K. R., Tanabe, K., and Andoh, T. Inhibition of intracellular topoisomerase II by antitumor bis(2, 6-dioxopiperazine) derivatives: mode of cell growth inhibition distinct from that of cleavable complex-forming type inhibitors Cancer Res., 51: 4909-4916, 1991.
27. Chen, M , and Beck, W. T. Differences in inhibition of chromosome separation and G2 arrest by DNA topoisomerase II inhibitors merbarone and VM-26. Cancer Res., 55: 1509-1516, 1995.
28. Downes, C. C., Clarke, D. J., Mullinger, A. M , Glme'nez-Abla'n, J. F., Creighton, A. M., and Johnson, R. T. A topoisomerase II-dependent G2 cycle checkpoint in mammalian cells. Nature (Lond.), 372: 467-470, 1994.
29. Ishida, R., Sato, M., Narita, T., Utsumi, K. R., Nishimoto, T , Morita, T., Nagata, H , and Andoh, T. Inhibition of DNA topoisomerase II by ICRF-193 induces polyploidization by uncoupling chromosome dynamics from other cell cycle events J Cell Biol., 126: 1340-1351, 1994.
30. Harker, W. G , Slade, D. L., Drake, F. H., and Parr, R. L. Mitoxantrone resistance in HL-60 leukemia cells: reduced nuclear topoisomerase II catalytic activity and drug- induced DNA cleavage in association with reduced expression of the topoisomerase IIβ isoform. Biochemistry, 30: 9953-9961, 1991.
31. Norman, M. R., and Thompson, E. B Characterization of a glucocorticoid-sensitive human lymphoid cell line. Cancer Res., 37: 3785-3791, 1977.
32. Wolverton, J S., Danks, M. K., Granzea, B., and Beck, W. T. DNA topoisomerase II immunostaining in human leukemia and rhabdomyosarcoma cell lines and their responses to topoisomerase II inhibitors. Cancer Res., 52. 4248-4253, 1992
33. Boege, F., Andersen A., Jensen, S., Zeidler, R , Kreipe, H. Proliferation-associated nuclear antigen Ki-Sl is identical with topoisomerase IIα. Delineation of a carboxy- terminal epitope with peptide antibodies. Am. J. Pathol , 146: 1302-1308, 1995.
34. Laemmli, U. K. Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature (Lond.), 227. 680-685, 1970.
35. Friche, E , Danks, M. K , Schmidt, C. A , and Beck, W. T. Decreased DNA topoisomerase II in daunorubicin-resistant Ehrlich ascites tumor cells. Cancer Res., 51: 4213-4218, 1991.
36. Baker, S. D , Wadkins, R. M., Stewart, C. F., Beck, W T., and Danks, M. K. Cell cycle analysis of amount and distribution of nuclear DNA topoisomerase I as determined by fluorescence digital imaging microscopy. Cytometry, 19: 134-145, 1995.
37. Beck, W T., Cirtain, M C., Danks, M. K , Felsted, R L , Safa, A. R., Wolverton, J. S., Suttle, D. P., and Trent, J M. Pharmacological, molecular, and cytogenetic analysis of "atypical" multidrug-resistant human leukemic cells. Cancer Res., 47: 5455-5460, 1987
38. Hill, A. B., Beck, W. T , and Trent, J. M Cytogentic and molecular characterization of tumors in nude mice derived from a multidrug-resistant human leukemia cell line. Cancer Res., 48: 393-398, 1988.
39. Kaneda, N., Nagata, H. and Yokokura, T. Metabolism and pharmacokinetics of camptothecin analog CPT-11 in the mouse. Cancer Res , 50: 1715-1720, 1990.
40. Kunimoto, T., Nitta, K , Tanaka, T., Uehara, N., Baba, H., Takeuchi, M , Yokokura, T., Sawada, S., Miyasaka, T., and Mutai, M. Antitumor activity of 7-ethyl-10-[4-(1- pipendino)-1-piperidino]carbonyloxy-camptothecin, a novel water-soluble derivative of camptothecin, against murine tumors Cancer Res., 47: 5944-5947, 1987
41. Beck, W T , Danks, M. K., Wolverton, J S., Kim, R., and Chen, M. Drug resistance associated with altered DNA topoisomerase II. Adv Enzyme Regul., 33: 113-127, 1993
42. Danks, M. K., Schmidt, C. A , Cirtain, M. C , Suttle, P , and Beck, W. T. Altered catalytic activity and DNA cleavage by DNA topoisomerase II from human leukemic cells selected for resistance to VM-26 Biochemistry, 27: 8861-8869, 1988.
43. Bugg, B. Y., Danks, M. K., Beck, W T., and Suttle, D. P. Expression of mutant DNA topoisomerase II in CCRF-CEM human leukemia cells selected for resistance to teniposide. Proc Natl Acad. Sci. USA, 88. 7634-7638, 1991
44. r 170,000 isozyme of DNA topoisomerase II in human tumor cells Cancer Res., 53: 1373-1379, 1993.
45. Fattman, C., Allan, W. P., Hasinoff, B. B., and Yalowich, J C. Collateral sensitivity to the bisdioxopiperazine, ICRF-187, in etoposide (VP-16)-resisiant human leukemia K562 cells Proc. Am. Assoc Cancer Res., 36: 317, 1995.
46. Beck, W. T., Danks, M. K., Wolverton, J. S., Chen, M., Granzen, B., Kim, R., and Suttle, D. P Resistance of mammalian tumor cells to inhibitors of DNA topoisomerase II. Adv Pharmacol., 29B. 145-169, 1994.
47. de Jong, S., Zijlstra, J G., Mulder, N H., and de Vries, E. G E. Lack of cross-resistance to fostriecin in a human small-cell lung carcinoma cell line showing topoisomerase II-related drug resistance Cancer Chemother. Pharmacol., 28: 461-464, 1991.
48. Sørensen, B. S., Sinding, J., Andersen, A. H., Alsner, J., Jensen, P. B. and Westergaard, O. Mode of action of topoisomerase II-targeting agents at a specific DNA sequence. J. Mol. Biol., 228. 778-786, 1992.
49. Jensen, P. B., Sørensen, B. S. Sehested, M., Demant, E. J. F., Kjeldsen, E., Friche, E. and Hansen, H. H. Different modes of anthracycline interaction with topoisomerase II. Biochem. Pharmacol., 45: 2025-2035, 1993.
50. Pérez, C., Campayo, L., Navarro, P., Garcia-Bermejo, L., and Aller, P. The action of the DNA intercalating agents 4′-(9-acridinylamino) methanesulphon-m-aniside and human promonocytic cells: relationship between cell cycle and differentiation. Biochem. Pharmacol., 48: 75-82, 1994.
51. Earnshaw, W. C., Halligan, B., Coke, C. A., Heck, M. M. S., and Liu, L. F. Topoisomerase II is a structural component of mitotic chromosome scaffolds. J. Cell Biol., 100: 1706-1715, 1985.
52. Taagepera, S., Rao, P. N., Drake, F. H., and Gorbsky, G. J. DNA topoisomerase IIα is the major chromosome protein recognized by the mitotic phosphoprotein antibody MPM-2. Proc Natl. Acad. Sci. USA, 90: 8407-8411, 1993.
53. Per, S. R., Mattern, M. R., Mirabelli, C. K., Drake, F. H., Johnson, R. K., and Crooke, S T. Characterization of a subline of P388 leukemia resistant to amsacrine: evidence of altered topoisomerase II function Mol. Pharmacol., 32. 17-25, 1987.
54. Evans, C. D., Mirski, S. E. L., Danks, M. K., and Cole, S. P. C Reduced levels of topoisomerase IIα and IIβ in a multidrug-resistant lung-cancer cell line. Cancer Chemother. Pharmacol., 34: 242-248, 1994.
55. Brown, G. A., McPherson, P., Gu, L., Hedley, D. W., Toso, R., Deuchars, K. L , Freedman, M. H., and Goldenberg, G. J. Relationship of DNA topoisomerase IIα and β expression to cytotoxicity of antineoplastic agents in human acute lymphoblastic leukemia cell lines. Cancer Res., 55: 78-82, 1995.
56. Chen, M., and Beck, W. T. DNA topoisomerase II expression, stability, and phosphorylation in two VM-26-resistant human leukemic CEM sublines. Oncol. Res., 7: 109-117, 1995.
57. Drake, F. H., Hofmann, G A., Bartus, H. F., Mattern, M. R., Crooke, S. T , and Mirabelli, C. K Biochemical and pharmacological properties of p170 and p180 forms of topoisomerase II. Biochemistry, 28: 8154-8160, 1989.
58. Petrov, P., Drake, F. H., Loranger, A., Huang, W., and Hancock, R. Localization of DNA topoisomerase II in Chinese hamster fibroblasts by confocal and electron microscopy. Exp Cell Res., 204: 73-81, 1993.
59. Zini, N., Santi, S., Ognibene, A., Neri, L. N., Valmori, A., Mariani, E , Negri, C , Astaldi-Ricotti, B., and Maraldi, N. M. Discrete localization of different topoisomerases in HeLa and K562 cell nuclei and subnuclear fractions. Exp. Cell Res., 270: 336-348, 1994.
60. Woessner, R. D., Mattern, M. R , Mirabelli, C. K., Johnson, R. K., and Drake, F H. Proliferation- and cell cycle-dependent differences in expression of the 170 kilodalton and 180 kilodalton forms of topoisomerase II in NIH-3T3 cells Cell Growth & Differ , 2: 209-214, 1991
61. Kimura, K., Saijo, M., Ui, M., and Enomoto, T. Growth state- and cell cycle- dependent fluctuation in the expression of two forms of DNA topoisomerase D and possible specific modification of the higher molecular weight form in the M phase. J. Biol Chem., 269: 1173-1176, 1994
62. Yang, C. J., Horton, J. K., Cowan, K. H., and Schneider, E. Cross-resistance to camptothecin analogues in a mitoxantrone-resistant human breast carcinoma cell line is not due to DNA topoisomerase I alterations. Cancer Res., 55: 4004-4009, 1995.
63. Kawato, Y., Aonuma, M., Hirota, Y., Kuga, H., and Sato, K. Intracellular roles of SN-38, a metabolite of the camptothecin derivative CPT-11, in the antitumor effect of CPT-11 Cancer Res., 51: 4187-4191, 1991.
64. Andoh, T., Ishii, K., Suzuki, Y., Ikegami, Y., Kusunoki, Y., Takemoto, Y., and Okada, K. Characterization of a mammalian mutant with a camptothecin-resistant DNA topoisomerase I. Proc. Natl. Acad Sci. USA, 84: 5565-5569, 1987.
65. Niimi, S., Nakagawa, K., Sugimoto, T., Nishio, K., Fujiwara, Y., Yokoyama, S., Terashima, Y., and Saijo, N. Mechanism of cross-resistance to a camptothecin analogue (CPT-11) in a human ovarian cancer cell line selected by cisplatin. Cancer Res., 52: 328-333, 1992.
66. Hsiang, Y., Hertzberg, R., Hecht, S., and Liu, L. F. Camptothecin induces protein- linked DNA breaks mediated via mammalian DNA topoisomerase I. J. Biol. Chem , 260: 14873-14878, 1985.
67. Takeda, S., Shimazoe, T., Sato, K., Sugimoto, Y., Tsuruo, T., and Kano, A. Differential expression of DNA topo I gene between CPT-11-acquired and native-resistant human pancreatic tumor cell lines detected by RNA/PCR-based quantitation assay. Biochem. Biophys. Res. Commun., 184: 618-625, 1992.
68. Kijima, T., Kubota, N., and Nishio, K. Establishment of a CPT-11-resistant human ovarian cancer cell line. Anti-Cancer Res., 14: 799-803, 1994.
69. Saijo, N., Nishio, K., Kubota, N., Kanzawa, F , Shinkai, T., Karato, A , Sasaki, Y., Eguchi, K., Tamura, T. Ohe, Y., Oshita, F., and Nishio, M. 7-Ethyl-10-[4-(1- piperidino)-1-piperidino] carbonyloxy camptothecin: mechanism of resistance and clinical trials. Cancer Chemother. Pharmacol., 34 (Suppl.): S112-S117, 1994.
70. Kanzawa, F., Sugimoto, Y., Minato, K , Kasahara, K , Bungo, M., Nakagawa, K., Fujiwara, Y., Liu, L. F , and Saijo, N. Establishment of a camptothecin analogue (CPT-11)-resistant cell line of human non-small cell lung cancer, characterization and mechanism of resistance Cancer Res., 50: 5919-5924, 1990.
71. Andoh, T., and Okada, K. Drug resistance mechanisms of topoisomerase I drugs. Adv. Pharmacol., 29B: 93-103, 1994.
72. Minato, K., Kanzawa, F , Nishio, K., Nakagawa, K., Fujiwara, Y., and Saijo, N. Characterization of an etoposide-resistant human small-cell lung cancer cell line. Cancer Chemother. Pharmacol., 26: 313-317, 1990.
73. Takigawa, N., Ohnishi, T., Ueoka, H., Kiura, K., and Kimura, I. Establishment and characterization of an etoposide-resistant human small cell lung cancer cell line. Acta Medica Okayama, 46. 203-212, 1992.
74. Kubota, N., Nishio, K., Takeda, Y., Ohmori, T., Funayama, Y., Ogasawara, H., Ohira, T., Kunikane, H., Terashima, Y., and Saijo, N. Characterization of an etoposide- resistant human ovarian cancer cell line Cancer Chemother. Pharmacol., 34: 183-190, 1994.
75. Sugimoto, Y., Tsukahara, S., Oh-hara, T., Isoe, T , and Tsuruo, T. Decreased expression of DNA topoisomerase I in camptothecin-resistant tumor cell lines as determined by a monoclonal antibody. Cancer Res., 50: 6925-6930, 1990.
76. Gupta, R. S., Gupta, R., Eng, B., Lock, R. B., Ross, W. E., Hertzberg, R. P., Caranfa, M. J., and Johnson, R. K. Camptothecin-resistant mutants of Chinese hamster ovary cells containing a resistant form of topoisomerase I. Cancer Res., 48, 6404-6410, 1988.
77. Tan, K. B., Mattern, M. R., Eng, W. K., McCabe, F. L., and Johnson, R. K. Nonproductive rearrangement of DNA topoisomerase I and II genes: correlation with resistance to topoisomerase inhibitors. J. Natl. Cancer Inst., 81: 1732-1735, 1989.
78. Leferre, D., Riou, J. F., Ahomadadybe, J. C., Zhou, D , Benard, J , and Riou, G. Study of molecular markers of resistance to mAMSA in a human breast cancer cell line. Biochem. Pharmacol., 41. 1967-1979, 1991.